A new type of checkpoint inhibitor from an Israeli biotech company called Compugen is showing early signs of halting tumor growth in patients with advanced cancer, offering hope that more patients might one day benefit from cancer immunotherapy.
The worry is that the encouraging data being presented Monday at the American Association for Cancer Research’s virtual annual meeting might oversell its promise, and it will later fall short like other, similar efforts.
About the Author Reprints
